Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings
Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now.
Immunovant Inc. (IMVT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 9,728,845 | $156,828,981 | +3% | 4.38% |
| 2. | Armistice Capital Steven Boyd | 5,836,000 | $94,076,320 | +13% | 1.4% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,457,881 | $87,981,042 | 0.64% | |
| 4. | Point72 Asset Management Steve Cohen | 3,442,078 | $55,486,307 | +4% | 0.09% |
| 5. | Two Seas Capital Sina Toussi | 2,762,040 | $44,524,085 | +23% | 0.71% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.00 | 16,666,666 | $349,999,986.00 | 113,317,007 | 2025-12-12 | Filing | |
| $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 | 2025-01-13 | Filing | |
| $38.00 | 1,526,316 | $58,000,008.00 | 79,805,331 | 2023-10-02 | Filing | |
| $6.00 | 416,667 | $2,500,002.00 | 73,805,331 | 2022-10-06 | Filing | |
| $5.60 | 15,000 | $84,000.00 | 20,000 | 2022-09-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.38 | 2,284 | $62,535.92 | 149,930 | 2025-12-18 | Filing | |
| $26.78 | 8,529 | $228,406.62 | 152,214 | 2025-12-18 | Filing | |
| $23.95 | 2,898 | $69,407.10 | 85,852 | 2025-12-01 | Filing | |
| $23.14 | 19,351 | $447,782.14 | 88,750 | 2025-12-01 | Filing | |
| $23.96 | 1,909 | $45,739.64 | 120,773 | 2025-12-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,729,555 | $237,440,423 | 0.01% | |
| 2. | 6,826,810 | $110,048,178 | 0% | |
| 3. | 5,738,236 | $92,500,364 | 0% | |
| 4. | 2,892,618 | $46,629,002 | 0% | |
| 5. | 2,754,731 | $44,406,264 | 9% |
News See All
12 Best Short Squeeze Stocks to Buy Right Now
As the year comes to a close, investors are keeping close tabs on the Federal Reserve's impending policy move, given the US shutdown-induced data shortage.
Immunovant, Inc. (NASDAQ:IMVT) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to the Roivant Second Quarter 2025 Earnings Call. [Operator Instructions] Please note that today's conference is being recorded.
Immunovant, Inc. (NASDAQ:IMVT) Q2 2026 Earnings Call Transcript
Operator: Thank you for standing by. Welcome to the Roivant Second Quarter 2025 Earnings Call. [Operator Instructions] Please note that today's conference is being recorded.
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results
According to Immunovant Inc. (NASDAQ:IMVT), it is set to announce the results of its financial and operating highlights before market open on November 10, 2025.
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37
Immunovant, Inc. (NASDAQ:IMVT) is one of the best biotech stocks with high potential. On September 30, JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant, Inc.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
Where is Immunovant (IMVT) Heading According to Analysts?
Immunovant, Inc. (NASDAQ:IMVT) is one of the best strong buy stocks to invest in according to Wall Street.
12 Best Strong Buy Stocks to Invest in According to Wall Street
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data...
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.